Medical/Pharmaceuticals
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
2021-04-19 20:15
2525
Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy
SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...
2021-04-19 20:00
5043
PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC
DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...
2021-04-19 20:00
1979
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...
2021-04-19 08:00
2018
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide
SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...
2021-04-16 18:29
5915
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functio...
2021-04-16 08:00
1654
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...
2021-04-15 18:20
6063
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
HANGZHOU, China, April 14, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center inChin...
2021-04-15 09:00
2841
Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing
SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, recently announced a strategic partnership with Hain...
2021-04-14 22:18
6163
Molecular Matrix and GenScript Partner to Launch SARS-CoV-2 Neutralizing Antibody Testing Service for Public
PISCATAWAY, New Jersey and WEST SACRAMENTO, Calif., April 13, 2021 /PRNewswire/
--Molecular Matrix, Inc.
2021-04-13 19:30
2108
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Rese...
2021-04-13 14:55
4297
PharmAbcine presents the non-clinical data of PMC-309 at AACR 2021
DAEJEON, South Korea, April 12, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring the non-clinical data of PMC-309 at American Associatio...
2021-04-12 20:00
1965
SkinPen® Precision Now Under Direct Management in the United Kingdom and Ireland
DALLAS, April 12, 2021 /PRNewswire/ -- Crown Aesthetics, a division of Crown Laboratories, Inc., is delighted to announce that SkinPen Precision, the first microneedling device cleared by the FDA and the gold standard for skin remodeling technology, now has a direct presence in the UK andIreland....
2021-04-12 17:32
1324
Yiling Pharmaceutical doubled its performance through innovation in 2020
SHIJIAZHUANG, China, April 12, 2021 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) released its 2020 annual report on Thursday. It achieved an operating revenue ofRMB 8.782 billion in 2020, with a year-on-year growth of 50.76%; and net profit attributed to equity holders ofRMB 1.219 billion, w...
2021-04-12 17:07
5326
Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long...
2021-04-10 21:33
6235
Bionomics Successfully Completes A$22.9 million Equity Raise
ADELAIDE, Australia, April 9, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on8 March 2021 (Entitlement Offer) and concurrent placement that was announced on17 March 2021 (Concurr...
2021-04-09 18:00
7659
Control Bionics (ASX:CBL) Partners with Numotion as Northeastern U.S. Reseller of Assistive Technology Solutions
Strategic Partnership Offers Customers More Access to Control Bionics' Industry-Leading Trilogy Product Line MILFORD, Ohio and NEW SOUTH WALES, Australia, April 9, 2021 /PRNewswire/ -- Control Bionics, a global assistive technology company specializing in speech generating devices, announced it ...
2021-04-09 04:16
1737
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting onJune 4-8 2021. Results from the first Phase 1 study of MVR-T3011 as an intr...
2021-04-08 20:47
2863
Hyundai Bioscience leads in the repurposing of Niclosamide
SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...
2021-04-08 17:17
2656
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...
2021-04-07 06:00
5882
Week's Top Stories
Most Reposted
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 305 media titles]
2026-04-01 09:00
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 302 media titles]
2026-03-31 13:53
DayOne Announces RM28+ Billion Commitment and Talent Initiatives in Malaysia at Inaugural Tech & AI Career Expo
[Picked up by 291 media titles]
2026-04-01 22:23
Most Read
Herbalife to Expand Its Personalized Nutritional Supplement Capabilities Through Planned Acquisition of Bioniq
2026-03-30 12:00
6647
